Research Site

Tatabánya 2800

1 studies enrolling now · 14 studies all time

What they study most

Acute Kidney Injury, Advanced or Metastatic Breast Cancer, Anemia, Asthma, Chronic Obstructive Pulmonary Disease, Colorectal Cancer, Diabetes Mellitus, Eosinophilic Chronic Rhinosinusitis, Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer, Multiple Sclerosis, Nasal Polyposis, Non-Small Cell Lung Cancer

Studies at this site

• A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. — Recruiting now
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer — Recruiting now
• AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer — Completed
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer — Completed
• Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer — Running, not enrolling
• Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) — Stopped early
• Dimethyl Fumarate (DMF) Observational Study — Completed
• A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma — Completed
• Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis — Completed
• Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. — Completed
• First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX — Completed
• A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease — Completed
• Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease — Completed
• A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD — Completed